{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T04:05:28Z","timestamp":1794110728268,"version":"4.8.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100021051","name":"Cabaletta Bio Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021051","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ymthe.2024.09.009","type":"journal-article","created":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T17:47:59Z","timestamp":1725731279000},"page":"3821-3828","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["Case study of CD19 CAR T therapy in a subject with immune-mediate necrotizing myopathy treated in the RESET-Myositis phase I\/II trial"],"prefix":"10.1016","volume":"32","author":[{"given":"Jenell","family":"Volkov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Nunez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahseen","family":"Mozaffar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Stadanlick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mallorie","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Vorndran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jazmean","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Cicarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quynh","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Furmanak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Hadi-Nezhad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0109-7997","authenticated-orcid":false,"given":"Samik","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2024.09.009_bib2","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ymthe.2024.09.009_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2022.102257","article-title":"Current and new targets for treating myositis","volume":"65","author":"Moghadam-Kia","year":"2022","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.ymthe.2024.09.009_bib4","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMc1506827","article-title":"Inflammatory Muscle Diseases","volume":"373","author":"Dalakas","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.09.009_bib5","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.autrev.2016.12.006","article-title":"Sj\u00f6gren's syndrome-associated myositis with germinal centre-like structures","volume":"16","author":"Espitia-Thibault","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.ymthe.2024.09.009_bib6","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.3389\/fimmu.2018.01372","article-title":"CD19(+)CD24(hi)CD38(hi) B Cells Are Expanded in Juvenile Dermatomyositis and Exhibit a Pro-Inflammatory Phenotype After Activation Through Toll-Like Receptor 7 and Interferon-alpha","volume":"9","author":"Piper","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2024.09.009_bib7","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jaut.2019.04.001","article-title":"Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients","volume":"101","author":"Betteridge","year":"2019","journal-title":"J.\u00a0Autoimmun."},{"key":"10.1016\/j.ymthe.2024.09.009_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1051609","article-title":"Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: A systematic review and meta-analysis","volume":"13","author":"Zhen","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2024.09.009_bib9","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ymthe.2024.09.009_bib10","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.kint.2019.12.025","article-title":"Anti-CD20-mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectives","volume":"97","author":"Crickx","year":"2020","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymthe.2024.09.009_bib11","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1136\/annrheumdis-2018-214898","article-title":"Non-response to rituximab therapy in rheumatoid arthritis is associated with incomplete disruption of the B cell receptor repertoire","volume":"78","author":"Pollastro","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ymthe.2024.09.009_bib12","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2016-01-694356","article-title":"Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy","volume":"128","author":"Bhoj","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.09.009_bib13","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T\u00a0cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2024.09.009_bib1","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.09.009_bib14","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.medj.2024.03.002","article-title":"CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis","volume":"5","author":"Fischbach","year":"2024","journal-title":"Med"},{"key":"10.1016\/j.ymthe.2024.09.009_bib15","article-title":"6 months-follow up data of systemic sclerosis patients treated with CD 19 targeting CAR-T cells","volume":"75","author":"Bergmann","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.ymthe.2024.09.009_bib16","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1136\/annrheumdis-2023-eular.3842","article-title":"First evidence for efficacy of CAR T\u00a0cell treatment in refractory antisynthetase syndrome","volume":"82","author":"Taubmann","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ymthe.2024.09.009_bib17","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1093\/rheumatology\/kead330","article-title":"Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T-cells after failure of several B cell depleting antibodies","volume":"63","author":"Taubmann","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ymthe.2024.09.009_bib18","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2315990121","article-title":"Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR-T cell therapy","volume":"121","author":"Qin","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2024.09.009_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1019972","article-title":"Anti-SRP immune-mediated necrotizing myopathy: A critical review of current concepts","volume":"13","author":"Ma","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2024.09.009_bib20","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.nmd.2017.09.016","article-title":"224th ENMC International Workshop:: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016","volume":"28","author":"Allenbach","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2024.09.009_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.08.023","article-title":"Cytokine and reactivity profiles in SLE patients following anti-CD19 CART therapy","volume":"31","author":"Nunez","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2024.09.009_bib22","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.4049\/jimmunol.1901120","article-title":"BAFF Produced by Neutrophils and Dendritic Cells Is Regulated Differently and Has Distinct Roles in Antibody Responses and Protective Immunity against West Nile Virus","volume":"204","author":"Giordano","year":"2020","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2024.09.009_bib23","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.3389\/fimmu.2019.02458","article-title":"Challenges and Opportunities for Consistent Classification of Human B Cell and Plasma Cell Populations","volume":"10","author":"Sanz","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2024.09.009_bib24","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","article-title":"CD19-targeted CAR T\u00a0cells in refractory antisynthetase syndrome","volume":"401","author":"M\u00fcller","year":"2023","journal-title":"Lancet."},{"key":"10.1016\/j.ymthe.2024.09.009_bib25","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.146743","article-title":"Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies","volume":"6","author":"Walti","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2024.09.009_bib26","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2024.09.009_bib27","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/1479-5876-9-138","article-title":"Biomarkers in T\u00a0cell therapy clinical trials","volume":"9","author":"Kalos","year":"2011","journal-title":"J.\u00a0Transl. Med."},{"key":"10.1016\/j.ymthe.2024.09.009_bib28","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1056\/NEJMoa1504542","article-title":"Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma","volume":"373","author":"Garfall","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.09.009_bib29","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1158\/1078-0432.CCR-22-0822","article-title":"Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19","volume":"28","author":"Diorio","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2024.09.009_bib30","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41571-021-00530-z","article-title":"A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains","volume":"18","author":"Cappell","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2024.09.009_bib31","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.09.009_bib32","doi-asserted-by":"crossref","first-page":"5737","DOI":"10.1182\/bloodadvances.2021006293","article-title":"Preferential expansion of CD8+ CD19-CAR T\u00a0cells postinfusion and the role of disease burden on outcome in pediatric B-ALL","volume":"6","author":"Talleur","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2024.09.009_bib33","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2024.09.009_bib34","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/acr.20035","article-title":"Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies","volume":"62","author":"Rider","year":"2010","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.ymthe.2024.09.009_bib35","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bdq.2014.08.001","article-title":"Determining lower limits of detection of digital PCR assays for cancer-related gene mutations","volume":"1","author":"Milbury","year":"2014","journal-title":"Biomol. Detect. Quantif."},{"key":"10.1016\/j.ymthe.2024.09.009_bib36","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1208\/s12248-021-00560-6","article-title":"Insights on Droplet Digital PCR-Based Cellular Kinetics and Biodistribution Assay Support for CAR-T Cell Therapy","volume":"23","author":"Sugimoto","year":"2021","journal-title":"AAPS J."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624005914?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624005914?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:28:51Z","timestamp":1783020531000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001624005914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S1525001624005914"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.09.009","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Case study of CD19 CAR T therapy in a subject with immune-mediate necrotizing myopathy treated in the RESET-Myositis phase I\/II trial","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Cabaletta Bio. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}